OOIR: Observatory of International Research

Papers

(The TQCC of Lancet HIV is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Optimising anal cancer screening through risk stratification	337
Lenacapavir: an attractive option, but proceed with caution	165
Risk estimation in HIV reveals our usual blind spots	151
Controversial chronicler of LGBTQ rights	115
A moment of reckoning	112
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	107
Are we ready for long-acting HIV treatment for adolescents?	107
Correction to Lancet HIV 2022; 9: e791–800	105
How do we prevent anal cancer in people living with HIV?	97
The Australian AIDS crisis through the eyes of volunteers	92
HIV and COVID-19: juxtaposition of two pandemics	90
Evidence supports use of on-demand PrEP for HIV prevention	86
Lung cancer in people living with HIV	81
Transplant donation without discrimination	77
Argentina updates HIV laws	75
How much could long-acting PrEP cost in South Africa?	65
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	60
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	60
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	59
Steps toward quick and equitable roll-out of lenacapavir	59
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	57
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	55
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	55
All roads lead to Westminster: the infected blood scandal	55
Making America unhealthy again	54

Redefining care: injectable HIV treatment for adolescents	54
Recent gay Black history in the UK	52
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	52
Reducing HIV transmission in British Columbia, Canada	50
Sex as a biological variable in HIV-1 and schistosome co-infection	50
Dolutegravir in neonates: finally we are getting there!	49
WHO recommends lenacapavir for HIV prevention	48
A public health approach to drug use crucial to ending AIDS	46
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	46
Equitable access to long-acting PrEP on the way?	46
Game-changing study of second-line HIV treatment	45
Unheard testimony	44
Gains and gaps: addressing HIV in diverse sex worker groups	44
Stigma reduction is key to improving the HIV care continuum	43
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	43
Suicide prevention research is crucial to achieving health equity for people with HIV	43
Integration of sexual health and HIV services	43
Fate of people with HIV in jeopardy in Ukraine	43
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	42
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	42
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	39
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	38
Standardisation of monitoring routines for new long-acting antiretrovirals in development	38
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	37
An eventful conference	37
Advancing the prevention and treatment of HIV in children: priorities for research and development	36
How can Africa sustain its HIV response amid US aid cuts?	36
Use of WHO paediatric weight-band dosing in drug labels	36
HIV self-testing: from availability to strategic deployment	35
Eliminating HIV in the UK among men who have sex with men	34
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	34
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	34
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	33
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	33
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	33
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	33
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	33
The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	33
Preventing sexually transmitted infections in the age of PrEP	32
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	31
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	30
Reduction of HIV reservoir after stem cell transplantation	29
Highlights from the 25th International AIDS Conference	28
Effects of self-testing on HIV outcomes in west Africa	27
Coffee with IAS President Beatriz Grinsztejn	27
Second-line HIV treatments for adults in LMICs	27
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	26
Addressing partner violence to end infant HIV infection	26
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	25
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	24

MSM and HIV in the Middle East and north Africa	24
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	24
Metabolic implications and safety of dolutegravir use in pregnancy	24
Closing the gap to UNAIDS 95-95-95: Lesotho's success story	24
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	23
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	22
Implementation of PrEP in Latin America	22
Optimised second-line regimens in the public health approach	22
HIV-free generation within reach for Botswana	22
Correction to Lancet HIV 2025; 12: e691–700	21
Can treatment-as-prevention and PrEP reduce HIV incidence?	21
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	21
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	21
No woman left behind: achieving cervical cancer elimination among women living with HIV	20
Crucial need for improved pharmacovigilance in pregnancy	20
Intersectional climate justice, health equity, and HIV	20
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	20
Breast cancer survival in women living with HIV	19
Treatment of HIV and HBV coinfection	19
A field of possibilities for paediatric HIV	19
Integrase inhibitors hand us a new HIV clinical puzzle	19
Need for clear inclusion criteria in reviews of antiretroviral treatments	19
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	19
Point-of-care testing to achieve paediatric 95-95-95 targets	19
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	19
Complex response to HIV and tuberculosis in South Sudan	19
Can COVID-19 changes reduce stigma in African HIV clinics?	18
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	18
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	18
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	18
Unified health surveys for integrated health systems	18
The HIV vaccine quest: ethical and implementation challenges	18
Long-acting PrEP for adolescent girls and young women	18
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	18
Making PrEP easy	18
Realising long-acting ART as first-line treatment	17
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	17
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	17
HIV treatment in Russia on the brink of crisis	17
A new index to guide global drug policies	16
Activists step in to deliver PEP and PrEP in Mexico	16
HERO—providing support for those engaged in chemsex	16
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	16
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	16
Correction to Lancet HIV 2023; 10: e424–26	15
A career dedicated to public service	15
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	15
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	15
Improving outcomes for children in families with HIV	15
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	15
Critical illness due to infection in people living with HIV	15
Expanding options of child-friendly, single-tablet regimens for young children with HIV	15
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	15
PEPFAR reauthorisation hangs in the balance	14
Increased risk of mental illness in people with HIV	14
HIV-related CNS infections: translating DREAMM into reality	14
HIV viral suppression is key to healthy longevity	14
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	13
Correction to Lancet HIV 2025; 12: e473–84	13
Reimagining HIV prevention with artificial intelligence	13
Zvandiri—when medicines alone are not enough	13
Inherited fear: 40 years of HIV/AIDS in the UK	13
A research framework to support re-engagement and continuous engagement in HIV care	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	13
Tajikistan faces a crucial moment in HIV/AIDS response	13
Expanding PrEP treatment options with a potent anti-HIV antibody	13
Ending HIV in Chicago by 2030	13
Home delivery of ART: could this be a reality in South Africa?	12
Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study	12
Where does doravirine fit in current antiretroviral therapy?	12
Forgiveness of an intermittent HIV treatment strategy	12
Enhancing HIV prevention through systematic community engagement, learning, and response	12
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	12
Defining principles for a choice-based approach to HIV prevention	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11
Real-world safety of pre-exposure prophylaxis for HIV	11
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	11
HIV prevention for young African women is about choice	11
What future for HIV vaccines?	11
Long-acting PrEP: new opportunities with some drawbacks	11

Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	11
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	11
Screening for chlamydia and incidence of symptomatic infections	11
Putting people first in communication about HIV	11
Equitable access to PrEP is essential to reap its benefits	11
UK and US militaries update HIV policies	11
COVID-19 antivirals must not affect HIV drug supply	11
Response to Thailand's commitment to support community-led HIV services	11
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	11
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	10
Mexican perspective on the Mosaico HIV vaccine trial	10
Expansion of PrEP and PEP services in China	10
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	10
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	10
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	10
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	10
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	9
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	9
Legislation threat to services for LGBTQ+ people in Georgia	9
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	9
Artificial intelligence in HIV research, policy, and clinical care	9
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	9
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	9
Low-cost point-of-care urine test to enhance PrEP adherence	9
Do we need routine integrase resistance testing before starting antiretroviral therapy?	9
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
Russia spiralling into an HIV crisis	8
The urgent need for opioid agonist treatment in Russia	8
Use of mobile phone data in HIV epidemic control	8
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	8
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	8
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	8
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	8
Elton John AIDS Foundation plugging gaps in HIV funding	8
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	8
Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries	8
COP27 Climate Change Conference: urgent action needed for Africa and the world	8
Understanding and managing disordered sleep in people with HIV	8
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	8
Dolutegravir dosing with rifampicin	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
Due south: navigating volatile health research landscapes	8